a) concentrations than the controls. The negative findings in our study suggest these factors did not have a significant effect on the lipoprotein (a) concentrations in our patients. There was also no apparent relationship between lipoprotein (a) and either diabetes or hypertension in our study. We believe that our sub-group and logistic regression analysis validate the conclusion that lipoprotein (a) is not an independent risk factor in cerebrovascular disease in general, although it may playa role in younger stroke patients. REFERENCES Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein (a) and the risk of future stroke. lAMA 1995; 273: 1269-73 2 Alfthan G, Peikkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomelehto J, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis
The Hemocue B glucose analyser and neonatal blood glucose monitoring
In their publication,' Leonard and co-workers investigated the important issue of bedside glucose monitoring and concluded from their data, that in neonates hypoglycaemia cannot be reliably detected by the Hemocue glucose analyser. In addition, they considered the analysis too costly. Their results are in contradiction to earlier studies.i-' also they are not in agreement with our own data on 392 laboratory controlled Hemocue values. The publication also has some methodological shortcomings.
The authors wrongly assumed that the use of fluoride or oxalate additives inhibited glycolysis completely. Burrin et at. clearly state that, for absolute accuracy in comparison studies, the use of protein precipitants, immediate analysis or storage on ice is mandatory." The authors themselves mentioned the delay in laboratory analysis for up to 1h. Furthermore, the authors'
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own data on between-day and within-day precision of the Hemocue analyser indicated coefficients of variation of less than 5% which do not differ from quoted control values. In contrast, the precision of the employed laboratory method was not mentioned. Consequently, the use of inappropriate inhibitors of glycolysis, the time delay and uncertainty about laboratory precision make it likely, that laboratory values would be lower than Hemocue values; and at the same time could explain the unusual large variation of the differences. So sensitivity, specificity and positive predictive values strongly depend on the selected data pairs and cut off levels for hypoglycaemia. Unfortunately, the publication provided no information on the frequency distribution of hypo-normo-and hyperglycaemia.
In an ongoing study in our neonatal intensive care unit we are investigating whether Hemocue could be a substitute for laboratory analysis, we have so far documented 392 laboratory controlled Hemocue blood glucose values. Blood for laboratory analysis was collected using perchlorate as protein precipitant and both laboratory and Hemocue precision was tested. The coefficients of variation for between-days precision were 3-4% for Hemocue and 1-4% for laboratory (high glucose standards) and 2·9% for Hemocue and 4·1 % for laboratory (low glucose standardsj.?
Of 392 laboratory controlled glucose values, Hemocue indicated 57 hypoglycaemic values (blood glucose < 2·24 mmoljL). Amongst these, Hemocue gave only four false negative results, the laboratory values being greater than 1·84 mmoljL. Consequently, all of these false negative results were above the range of severe hypoglycaemia, defined as < \·4 mmoljL.
In summary, in 392 laboratory controlled glucose tests, the Hemocue did not miss a severe hypo glycaemia and demonstrated acceptable accuracy. Thus, neonatal hypoglycaemia can reliably be detected by the Hemocue and treated immediately reducing the risk of brain damage.
If the Hemocue could replace laboratory analysis in screening for glucose abnormalities, the true costs would differ from those the authors cited. Hemocue Leonard et al. ' have found that in new-born babies the Hemocue blood glucose analyser may overestimate the glucose concentration by as much as 2·5 mmol/L, Because of this, they conclude that the Hemocue analyser may be more useful in monitoring high blood glucose levels than in the detection of neonatal hypoglycaemia. We agree with this conclusion. Yet we think it is worthwhile drawing attention to a confounding observation, which we made in a similar (unpublished) study, and which also has been made by Ellis et al. 2 In our neonatal intensive care unit, we measured the glucose concentration in 141 samples of neonatal blood with a Hemocue glucose analyser and with an automated glucose oxidase method (GOM) using a flow-through euvet (ECA 180). The mean difference (Hemocue-GOM) was 1·6 mmol/L with a standard deviation of 0·8 mrnol/L, for a concentration range (GOM) of 1·2 to 15·5 mmol/L, The Hemocue overestimated the blood glucose at all concentrations; with only two cases where the Hemocue gave a lower value than the GOM.
In 124 samples we also determined the haernatocrit, which ranged from 27% to 65%. There was no significant correlation between the haematocrit and the difference between Hemocue and GOM.
In order to determine the imprecision of the Hemocue, we made 20 consecutive measurements of each of four blood samples obtained from healthy adult volunteers. The standard deviation was 0,1, O· 3, 0·1 and O· 3 mmol/L, corresponding with a coefficient of variation of 2'1, 7'1, 1'7, and 6·4%, respectively. The most striking finding however, was that the difference between the mean values of the four series and the gluose oxidase method was only 0'0, 0,5, 0,9, and O'5 mmol/L. Hence, we found for adult blood a difference between Hemocue and GOM of only 0'5mmol/ L against a difference of 1·6 mrnol/L for neonatal blood. Ellis et (/1. 2 assessed blood glucose in 94 new-born infants and in 75 of their mothers. In the neonates, the Hemocue overestimated the glucose concentration by 1·7 mrnol/L in comparison with a glucose oxidase method, whereas in the mothers the mean difference was only O' 3 rnrnol/L, Consequently, there seems to be a systematic difference between the results obtained in neonates and in adults. The factor causing this difference might also playa part in some other methods for measuring blood glucose. We speculate that the error originates in the photometric part of the Hernocue analyser. It may either be caused by a neonatal blood factor interfering with the colour development of the tetrazolium salt, or by a blood component absorbing at 660 and/or 840 nm.
The cause being in the difference in spectral absorbency between HbA and HbF cannot be ruled out, but seems improbable, because these differences arc very small at the wavelengths used.' With great interest we have read the article of Leonard 1'1 al, ' We have been using HemoCue B-Glucose analysers for more than 4 years in the neonatal ward, the Neonatal Intensive Care Unit and the delivery room of our hospital for point-of-care determinations of neonatal blood glucose and our experiences stand in total contrast to the findings of Leonard. Our own studies-4 showed only a very small bias between HemoCue and the reference method and a scatter of results, which did not exceed ± 0·25 mmol(L for concentrations below 6 mmol(L. Fresh capillary blood samples were used for all our measurements and the hexokinase method served as the reference method. These results are routinely confirmed by comparison measurements between Hemo-Cue B-Glucose and the central laboratory. Furthermore, in a recent paper the excellent accuracy of HemoCue results was demonstrated using 140 capillary blood samples and isotope dilution gas chromatography-mass spectrometry (10 GC-MS) as the reference method.' In contrast to the study by Hannestad, the data of Leonard 1'1 al. show a systematic difference of -0'75mmol(L and a scatter of about ± 1·75 mmol(L with outliers up to + 3( -4 mmol(L. Table I suggests that for measurements with control sera, the precision and accuracy of the HemoCue analyser seems to perform satisfactorily. No quality control data have been given for the comparison method (Beckman glucose analyser).
Although the Beckman analyser has proved to be reliable under routine conditions, there are several factors, which can influence the performance of its measurements. These range from instrument problems (e.g. imperfect circulation of reagent, electrode membrane covered with protein and soiled cuvette or stirrer) to pipetting problems (e.g. imprecision of the pipette and contamination with red blood cells). Surprisingly, the authors did not repeat their experiments with at least some samples from non-diabetic and diabetic adults. Such experiments would have established quickly and easily whether the problem related only to the glucose concentration of the samples, to their neonatal origin or, as I suggest, to other problems.
Although the authors cite several publications, which report poor accuracy of the HemoCue analyser, there are others which demonstrated opposite results.P H In that context, it should be noted that whole blood results cannot be compared with plasma results without a correction factor. None of all these papers show a scatter, which is comparable to Leonard's data. Many neonatologists face a dilemma: the literature questions the use of In a recent paper published in this Journal, Leonard 1'1 al,' found that in a neonatal ward the HemoCue analyser overestimates blood glucose by as much as 2'5rnmol(L compared to their Beckman glucose oxidase method. The mean difference was 0·75 mmol(L. Based on this data, they state that the HemoCue system 'cannot be relied upon to detect hypo glycaemia accurately'. Several reports.i" including our own,5 have shown HemoCue to be useful in the diagnosis Letters of neonatal hypoglycaemia. We therefore wish to discuss how such discrepancies can occur. Their Fig. I shows that Leonard et al. found nearly one-third of their patients to be in the hypoglycaemic range for full-term infants «2mmol(L); as judged from the average of HemoCue plus the laboratory glucose values at the abscissa (their Beckman results must have been even lower). Since such a clinical situation is not very likely, the finding probably indicates some technical error within their laboratory reference procedure.
Leonard obtained blood from a heel prick and transferred it into fluoride oxalate tubes. Hemo-Cue readers were performed immediately by the bedside and the samples were then sent for reference measurement by the laboratory. A delay up to 1 h in the laboratory before analysis was accepted. Several papersv" describe the inability of fluoride to prevent glycolysis during the first 1-3 h after blood collection. Glucose loss in blood stored for 1 h at room temperature can be between 10-15% at normal glucose concentration and normal haematocrit (approximately O'5 mmol(L). The loss is largely independent of the blood glucose concentration because glucose uptake by the erythrocytes is constant. Glycolysis will be increased at elevated haematocrit.v" as occurs in many newborns. Hence, much of the discrepancy between the two methods used by Leonard et al., 
Author's reply
In his letter, Dr Raile indicates that true comparisons of glucose can only be made using protein precipitation, immediate analysis or storage on ice, I and has provided data from samples after protein precipitation with perchlorate. Our study was conducted to reflect routine clinical practice and, as such, I am not aware of any laboratory in the UK using perchlorate precipitation routinely for glucose analysis. It is common practice, however, to collect blood for glucose measurement into tubes containing fluoride oxalate as a preservative. Dr Raile quite rightly points out our failure to include the imprecision of our laboratory analyser. Our Beckman CX7 analyser shows between day coefficient of variation's (n = 20) of 2·8%, 1'5%, 1·6% at glucose values of 2'5,6'3, 13·7mmol(L. This is in accordance with analytical goals as defined by Fraser.?
We do agree with Dr Raile that a delay in treatment of a hypoglycaemic neonate is unacceptable but the cut-off glucose level for hypoglycaemia remains a problem to define. Sensitivity and specificity at a level of 3 mmol(L is given in our original article as we consider this to be a reasonable cut-off level.' If <2'Ommol(L is regarded as hypoglycaemic" then, in our case, the Hemocue detected seven babies with glucose less than or equal to 2'Ommol(L whilst the laboratory detected 27 cases. It is for this reason that we adhere to strict protocols for using Hemocue analysers on our special-care baby unit (SCBU), which incorporate daily quality control measurements, monthly inspection and agreed protocols for laboratory confirmation of hypoglycaemia ( < 5 mmol(L).
The cost of running Hemocue analysers on our unit may not be directly comparable to other units and was included to point out that there are significant running costs involved in nearpatient testing as well as the laboratory cost. In
